CN107129527A - A kind of Malian drainage protective antigens HP0623 and preparation method thereof - Google Patents
A kind of Malian drainage protective antigens HP0623 and preparation method thereof Download PDFInfo
- Publication number
- CN107129527A CN107129527A CN201710395446.2A CN201710395446A CN107129527A CN 107129527 A CN107129527 A CN 107129527A CN 201710395446 A CN201710395446 A CN 201710395446A CN 107129527 A CN107129527 A CN 107129527A
- Authority
- CN
- China
- Prior art keywords
- sez
- malian drainage
- protective antigens
- malian
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to a kind of Malian drainage protective antigens HP0623 and preparation method thereof, the Malian drainage protective antigens HP0623 is SEZ HP0623 recombinant proteins, is made up of 429 amino acid residues, molecular weight is 47.04kDa;The preparation method includes gene cloning, digestion enzyme company, induced expression, protein purification;The HP0623 can be used for the preparation of vaccine.Malian drainage protective antigens HP0623 of the present invention shows good immune response originality in mouse experiment; the antibody of generation can provide stronger protection; the sterilizing ability of induced high levels; Malian drainage protective antigens HP0623 is located at SEZ surfaces, and rHP0623 can suppress adhesions of the SEZ to the cells of Hep 2.
Description
Technical field
The present invention relates to streptococcus protective antigens, specially a kind of Malian drainage protective antigens HP0623
And preparation method thereof.
Background technology
Streptococcosis is a kind of extremely common animal pathogen, and 20 can be classified as according to group specific antigen
Group, from A~V, lacks I and J.Animal pathogen is with B group streptococcus (Group B Streptococci, GBS) and C group streptococcus
(Group C Streptococci, GCS) is more, and the pathogenic bacteria of people are generally A group streptococcus (GroupA
Streptococci,GAS)。
Malian drainage (Streptococcus zooepidemicus, SEZ) belongs to C group's chains of Lan Shi points of groups
Coccus, no special preferendum of host, easily morphs, and different strain antigens of originating may be different.The bacterium can be through alimentary canal, hand
Art, wound, vaccinate with the approach infection animal such as wound, so as to cause the septicemia of animal, arthritis, mammitis, meninx
The animal epidemics such as scorching and endocarditis.People then may be by drawing with infected animal close contact or the food of edible bacterium pollution
Send out the sick infection.The antibiotic such as penicillin and Amoxicillin is used for prevention and treatment always, and this is sick, but due to antibiotic
Largely use, cause the bacterium drug resistance generation and antibiotic in animal product residual the problems such as.Therefore, prevented using vaccine
These problems can fundamentally be solved by controlling the disease.But it is due to that the whole-bacterial-vaccine of inactivation can often cause the pairs such as immune complex
Effect, it is therefore desirable to research and develop new subunit protein vaccine to prevent the generation of such disease.The sugar knot of cell surface grappling
Hop protein (HP0623) is a kind of newfound protective antigens of Malian drainage cell surface, and it is mainly acted on
Host cell, therefore it is expected to be developed to preventing and treating SEZ subunit vaccine.
The content of the invention
In order to solve the above problems, the invention provides a kind of Malian drainage protective antigens HP0623 and its
A kind of preparation method, Malian drainage protective antigens HP0623 can be sub- effective for preventing and treating streptococcus equi epizootic disease
Kind.
The technical scheme is that:
A kind of Malian drainage protective antigens HP0623, the HP0623 recombinant proteins are SEZ HP0623 weights
Histone (rHP0623), by sez_0623 gene codes, is made up of, molecular weight is 47.04kDa, ammonia 429 amino acid residues
Base acid sequence is as shown in SEQ ID NO.2.
A kind of Malian drainage protective antigens HP0623 preparation method, is comprised the steps of:
1) PCR is expanded:The use of Malian drainage SEZ C55138 pnca genes group is template, performing PCR is entered with primer
Amplification;
2) it is connected with carrier:PCR primer connects after digestion with restriction enzyme with the pET-32a carriers through same enzyme digestion
Connect;Described restriction enzyme is BamH I and Hind III;
3) convert and induce:The above-mentioned carrier conversion connected is entered after Escherichia coli (E.coli BL21), 37 are placed in
DEG C shaking table culture, when its OD value is 0.6~1.0, adds IPTG inductions 3-5h;
4) purify:Thalline is collected by centrifugation, after being resuspended through PBS, supernatant is collected by centrifugation after high pressure is broken, by the purpose of supernatant
Albumen carries out the HP0623 recombinant proteins that purifying obtains purifying by Ni-NTA chromatographic columns.
The primer includes forward primer and reverse primer, and the forward primer and reverse primer respectively have 1 restriction enzyme site.
Further, the primer is:
Forward primer (SEQ ID NO.3):5 '-CCCGGATCCGCTTGCCTGCTAGTG-3 ', dashed part is BamH I
Restriction enzyme site;
Reverse primer (SEQ ID NO.4):5 '-CTCAAGCTTGAGGGGAAGATCGTATC-3 ', dashed part is Hind
III digestion site;
Applications of the Malian drainage protective antigens HP0623 in Malian drainage vaccine is prepared.
The side of Malian drainage vaccine is prepared using the Malian drainage protective antigens HP0623
Method is:Recombinant protein by successful expression and Jing Guo purification process, i.e. Malian drainage protective antigens HP0623, with
As vaccine after Montanide Gel 01PR (SEPPIC, France) adjuvant emulsion, recombinant protein concentration described in vaccine is
100 μ g/mL, the concentration is the minimum effective concentration of recombinant protein in vaccine.
The present invention technique effect be:
Compared with prior art, the streptococcus equi beast that the present invention is purified by steps such as gene cloning, expression, purifying
Epidemic disease subspecies protective antigens HP0623 recombinant proteins.The present invention obtains target gene by round pcr first, is connected by digestion enzyme
Method obtain recombinant plasmid, be transferred in Escherichia coli progress induced expression HP0623 recombinant proteins, printed through protein immunization
Note experiment, shows that the recombinant protein has good immunogenicity.Mouse is immunized after adjuvant emulsion in HP0623 recombinant proteins can
To provide higher Vaccine effectiveness for it, two exempt from mice serum can provide preferable passive immune protection for mouse.Through
Mice serum after rHP0623 recombinant proteins are immune determines its antibody titer through ELISA, shows that recombinant protein can induce high level
Antibody titer, and immune response type is based on Th2.HP0623 recombinant proteins antibody can induce stronger sterilizing ability,
After SEZ infecting mouses, the transcriptional level of the SEZ extracted in its spleen tissue sez_0623 genes is higher than external training
Foster transcriptional level, rHP0623 can suppress SEZ to the adhesion of Hep-2 cells and infect.
Brief description of the drawings
Fig. 1 represent the SDS-PAGE and immunoblotting analysis figure of HP0623 albumen.
In Fig. 1, swimming lane 1~3 is respectively before recombination bacillus coli is induced, after induction and HP0623 albumen after purification;Swimming
Road M is albumen pre-dyed Marker.
Swimming lane 4 is the Westernblot testing results that rHP0623 and SEZ infects rehabilitation Swine serum.
Fig. 2, Fig. 3 are that immune response ELISA testing result figures caused by Mice Body are immunized after mouse in recombinant protein.
Antibody level in Fig. 2 for immune group and negative control group compares;The antibody response class induced in Fig. 3 for HP0623
Type compares.
Fig. 4 represents the mouse of immune group, negative control group and positive controls, after attacking poison through SEZ, the survival rate pair of mouse
Than figure.
Fig. 5 represents that rHP0623 bis- exempts from serum (experimental group), SEZ inactivated vaccines two and exempts from serum (positive controls) and normal
Serum (negative control group) provides the situation comparison diagram of passive immune protection for mouse.
Fig. 6 show the analysis result figure of quantitative PCR.
It is respectively three mouse each bacteria gene expression situation in spleen from left to right in Fig. 6.
Fig. 7, Fig. 8 are surface distributed figures of the flow cytometries HP0623 in SEZ.
Fig. 9 represent the lethal use comparative result figure of Mouse whole blood.
In Fig. 9,1 it is experimental group, 2 is that positive controls and 3 are negative control group.
Adhesion testing result figures of Figure 10 .SEZ to Hep-2 cells.
Embodiment
In order to be better understood from the present invention, it is described further below in conjunction with embodiment and accompanying drawing.
Normal experiment method and condition are used in the embodiment of the present invention, condition is not those skilled in the art in the present invention
Known to member, those skilled in the art can combine prior art and realize the present invention.
Embodiment one, bacterial strain and growth conditions
Bacterial strain is SEZ C55138 bacterial strains;Condition of culture is the TSB culture mediums or TSA culture mediums for adding 5% hyclone;
0.6~1.0 is reached in 37 DEG C of concussion and cultivate about 8h, or OD600.Carrier is Escherichia coli pET-32a, and competent cell is large intestine
Bacillus BL21.
The SEZ C55138 bacterial strains, Escherichia coli pET-32a, hyclone and e. coli bl21 competent cell are equal
For commercially available prod.
Embodiment two, preparation method
HP0623 albumen is by sez_0623 gene codes, and the HP0623 gene forward primers have 1 BamH I digestions position
Point, reverse primer has 1 Hind III digestions site.The forward and reverse primer is designed by SEZ genome sequences, by primer
Synesis Company synthesizes.
Malian drainage protective antigens HP0623 preparation method, is comprised the steps of:
1) PCR is expanded:Using the genome of C55138 bacterial strains as template, enter performing PCR using following primer and expand:
Forward primer (SEQ ID NO.3):5’-CCCGGATCCGCTTGCCTGCTAGTG-3 ', dashed part is BamH I
Restriction enzyme site;
Reverse primer (SEQ ID NO.4):5’-CTCAAGCTTGAGGGGAAGATCGTATC-3 ', dashed part is Hind
III digestion site;
2) it is connected with carrier:PCR primer use digestion with restriction enzyme after with the pET-32a carriers through same enzyme digestion
Connection;
3) convert and induce:After the above-mentioned carrier conversion competent escherichia coli cell BL21 connected, in 37 DEG C of perseverances
Treat that it, to exponential phase of growth, adds final concentration of 1mM IPTG, induce 3h in warm shaking table;Do non-induced check experiment simultaneously.
4) purify:Thalline after induction is collected by centrifugation, it is broken through high pressure after being resuspended with sterile PBS, recombinant protein is collected by centrifugation
Supernatant, the recombinant protein for the purifying that the destination protein in supernatant is obtained after Ni-NTA column chromatographies.
Immunoblotting analysis is analyzed:Recombinant protein after purification, primary antibody, goat are used as using the rehabilitation Swine serum for infecting SEZ
Anti- pig IgG (H+L)-HRP carries out immunoblotting assay as secondary antibody.
The genome of described C55138 bacterial strains is extracted from C55138 bacterial strains by conventional method and obtained.
Primer is synthesized by Wuhan Jin Kairui bioengineering Co., Ltd, and the restriction enzyme is BamH I and Hind
III。
IPTG is isopropyl-β-D-thiogalactoside, is the activity inducement material of beta galactosidase.It is special based on this
Property, when being converted with lacZ gene carrier DNA by host of lacZ deletion cells, it, which can be used as, has lac or tac etc.
The induced expression thing of the expression vector of promoter is used.
Experimental result
PCR obtains sez_0623 gene order (SEQ ID NO.1), by SEZ C55138 bacterial strain sez_0623 genes gram
After grand, the protein (SEQ ID NO.2) of 429 amino acid compositions is given expression to, molecular weight is 47.04kDa.Compare induction and
The bacterium of non-induced culture, can prove successful expression destination protein, and the stripe size and the size of prediction of destination protein
Unanimously.The recombinant protein of purifying is obtained by way of Ni-NTA affinity chromatographys, by immunoassay experiment show, the albumen with
Infection SEZ convalescence Swine serum shows good immunoreactivity, as shown in figure 1, HP0623 albumen size and prediction
It is in the same size, and it has good immune response originality.
Embodiment three, antibody titer are determined
By enzyme linked immunosorbent assay mice serum IgG antibody, by the recombinant protein HP0623 of purifying in 4 DEG C of mistakes
After night coating, the two mouse blood samplings after immune 10 days are separated after serum, gradient doubling dilution, all dilution factors take 100 μ
L adds elisa plate, and the mountain sheep anti-mouse igg of horseradish enzyme mark is added after 37 DEG C of reactions, terminating reaction after the completion of developing the color is waited, uses enzyme mark
Instrument reads OD values, takes OD values to be more than the serum maximum dilution multiple conduct of+3 times of variance SD (standard deviation) of control serum mean OD value
Serum antibody.In order to infer immunization type, further detect IgG1 and IgG2a to determine Th2 and Th1 immune response.
Experimental result:
The level of the IgG titres of immune group is significantly higher than the antibody level of negative control group, immune group as shown in Figure 2 it is anti-
Body titre is apparently higher than negative control group.
As a result show that HP0623 can cause significant Th1/Th2 immune responses, compared with the IgG2 antibody of generation, IgG1
Antibody titer is occupied an leading position, as shown in Figure 3 in the antibody response type that HP0623 is induced, and Th2 reactions are occupied an leading position.
Example IV, mice immunisation and challenge test
1st, 30 6~8 week old KM female mices are taken, 3 groups, every group 10 are randomly divided into;
2nd, experimental group:RHP0623 Montanide Gel 01PR (SEPPIC, the France) adjuvant emulsions of 50 μ g purifying
Afterwards, it is injected intraperitoneally and first group of mouse is immunized, interval carries out secondary immunity with dosage to mouse in the same way after 14 days;
3rd, positive controls:By C55138 plants of inactivations of SEZ, helped through Montanide Gel 01PR (SEPPIC, France)
After agent emulsification, with 1 × 109Second group of mouse is immunized in CFU/mL, by the way of intraperitoneal injection, and interval is after 14 days, same side
Formula carries out secondary immunity;
4th, negative control group:3rd group of 10 mouse be injected intraperitoneally through Montanide Gel 01PR (SEPPIC,
France) PBS of adjuvant emulsion is compareed;
5th, all mouse secondary immunities are after 10 days, and serum is collected by centrifugation in tail vein blood, and then all mouse attack malicious SEZ
C55138 bacterial strains (2 × 105CFU/mL);
6th, observe and record the growing state of all mouse.
Experimental result:
1) 10 mouse of experimental group, attack and start within the 3rd day after poison death occur, the mouse of survival shows slight face
Bed symptom, such as state of mind is poor, becomes thin, and was that full recovery is normal in 6 days, finally there is 4 dead mouses;
2) mouse of positive controls does not totally show obvious clinical symptoms, only has during entirely attacking poison 1 small
Mouse occurs dead;
3) mouse of negative control group starts death for second day after poison is attacked, and the mouse of survival shows obvious clinic
Symptom, such as hair are messy, and stimulate the reaction is blunt to external world, not active etc., and gradually dead in 6 days after poison is attacked, and finally only 1
Only survive.
As shown in figure 4, positive controls and immune group can provide higher immunoprotection, and positive controls for mouse
It is higher than experimental group.As a result show that restructuring rHP0623 albumen can provide immunoprotection for mouse, resist the sense of SEZ velogen strains
Dye.
Embodiment five, passive protection test analysis
It is to give the credit to the special immune response stimulatings of HP0623 to confirm to protect, exempts from serum with rHP0623 bis- and passively exempt from
Epidemic disease mouse, then carries out challenge test again.
1st, 30 6 week old KM female mices, are randomly divided into 3 groups, every group 10;
2nd, positive controls:Exempt from first group of mouse of serum intravenous immune with SEZ inactivated vaccines two;
3rd, negative control group:With second group of mouse of Normal Mouse Serum intravenous immune;
4th, experimental group:Exempt from the 3rd group of mouse of serum intravenous immune with rHP0623 bis-;
5th, it is immunized after 24h, all mouse carry out challenge test (2 × 10 with SEZ C55138 bacterial strains5CFU/mL);
6th, observe and record the growing state of all mouse.
Experimental result:
1) positive controls mouse does not show clinical symptoms in challenge test, there is 1 mouse during entirely attacking poison
It is final dead;
2) negative control group mouse is mainly shown as One's spirits are drooping after poison is attacked, and stimulate the reaction is slow to external world, hair is thick
The symptom such as random, and it is dead successively in 3 days;
3) experimental mice is mainly shown as One's spirits are drooping, slow, thick unrest of hair of stimulate the reaction etc. to external world after poison is attacked
Returned to normal after symptom, but 3 days, the final survival rate of mouse is 70%.
As shown in figure 5, as a result showing, experimental group and positive controls are significantly stronger than feminine gender to the passive protection ability of mouse
Control group.
Embodiment six, quantitative fluorescent PCR analysis
It is fixed by fluorescent quantitative PCR technique in order to assess expression of the SEZ sez_0623 genes inside and outside Mice Body
Transcriptional level inside and outside amount detection sez_0623 genosomes.
1st, propagation bacterium in vivo is obtained out of infection SEZ mouse spleen, sterile collection spleen tissue is milled after 4 DEG C,
850 × g centrifuges 5min, takes supernatant liquor in 4 DEG C, 15500 × g centrifugation 5min precipitate the bacterium in as spleen tissue;In vitro
Precipitation is collected by centrifugation after it grows into Midexponential in the bacterium of culture;
2nd, bacterium total serum IgE is extracted with sour phenol method;
3rd, it is cDNAs by RNA reverse transcriptions, quantitative PCR reaction is carried out by template of cDNA samples, all reactions carries out three
Repeat;
In real-time fluorescence quantitative PCR, quantitative analysis is carried out to sez_0623 genes using following primer:
Forward primer (SEQ ID NO.5):5’-CGGTATAGTATAGCCAAGC-3’;
Reverse primer (SEQ ID NO.6):5’-GCATTTCTCCCAACGA-3’;
In real-time fluorescence quantitative PCR, quantitative analysis is carried out to 16S rRNA genes using following primer:
Forward primer (SEQ ID NO.5):5’-ATCCGAACTGAGATTGGC-3’;
Reverse primer (SEQ ID NO.6):5’-CCCTTATGACCTGGGCTA-3’;
Experimental result:
As shown in fig. 6, as a result showing that the transcriptional level of the SEZ extracted in mouse spleen sez_0623 genes will obvious height
In the SEZ of in vitro culture transcriptional level.
Embodiment seven, flow cytometry
1st, bacterium is resuspended with PBS/BSA (PBS containing 1%BSA), takes the μ L of bacterium solution 200;
2nd, experimental group adds the μ L of mice serum 100 being immunized through rHP0623, and control group adds the mouse blood being immunized through PBS
Clear 100 μ L, 4 DEG C of incubation 15min, are then incubated at room temperature 30min;
3rd, 5000rpm centrifuges 3min, collects bacterium;
4th, washed with PBS/BSA 3 times, add FITC- mountains sheep anti mouse secondary antibody, 45min is incubated at room temperature;
5th, washed with PBS/BSA 3 times, be resuspended with 500 μ L PBS, be added in flow cytometer and detected.
Experimental result:
As shown in Figure 7, Figure 8, relative to blank control group, SEZ HP0623 antibody can cause stronger on SEZ surfaces
Fluorescence signal, control group bacterium average fluorescent strength is weaker, and the average fluorescent strength of experimental group bacterium has larger lifting,
Show that HP0623 albumen is distributed in SEZ surface.
Embodiment eight, the analysis of whole blood lethal dose
To determine after the bactericidal activity of HP0623 antibody, mouse blood test tube of hepari, serum is exempted from or right using rHP0623 bis-
It is estimated after being incubated according to serum with the SEZ survived in blood.
1st, treating, SEZ C55138 strain growths, to Midexponential, are collected by centrifugation thalline, bacterial concentration are adjusted with sterile PBS
For 104CFU/mL;
2nd, positive controls:Take 900 μ L healthy mices through anticoagulant heparin whole blood, serum is exempted from 100 μ LSEZ inactivated vaccines two
Mixing;
3rd, negative control group:Take 900 μ L healthy mices through anticoagulant heparin whole blood, mixed with 100 μ L Normal Mouse Serums;
4th, experimental group:Take 900 μ L healthy mices through anticoagulant heparin whole blood, exempt from serum with 100 μ L restructuring rHP0623 bis- and mix
Close;
5th, 100 μ L SEZ bacterium solutions are added into mixed liquor respectively, 37 DEG C of constant-temperature table concussion and cultivate 90min are placed in;
6th, every group takes 100 μ L samples respectively, is coated in TSA flat boards, carries out 3 repetitions, calculates the front and rear survival of hatching
Amount of bacteria;
7th, survival rate is calculated as remaining amount of bacteria relative to the percentage for starting amount of bacteria.
Experimental result:
Negative control group sterilizing rate is 9.21 ± 1.29%;Positive controls sterilizing rate is 91.6 ± 1.35%;Experimental group
Sterilizing rate is 61.08 ± 1.60%.
As shown in figure 9, as a result showing that anti-rHP0623 antibody can be with the sterilizing ability of induced high levels, anti-
HP0623 antibody can have stronger killing ability to SEZ.
Embodiment nine, adherence inhibition test
The influence of Hep-2 cells is adhered to SEZ for detection HP0623, is detected by the adherence test of Hep-2 cells,
Key step is as follows:
1st, the DMEM culture Hep-2 cells containing 10% hyclone are added in 24 orifice plates, 37 DEG C of cell trainings are placed on
Support in case and cultivate, treat its length to 80% or so;
2nd, cell is washed 3 times using the PBS/BSA of precooling;
3rd, the rSec_205 that 200 μ g/ml purifying is added per hole is incubated 2h, and identical cell adds 200 μ g/ml BSA
It is incubated as a control group;
4th, after the completion of being incubated, washed with PBS/BSA 3 times, 1ml 5 × 10 is then added into each hole7CFU/ml SEZ
C55138 plants in 37 DEG C, 5%CO2Under the conditions of be incubated 2h;
5th, nonadherent bacterium is washed away with PBS/BSA, then will be thin with 1ml PBS (the Triton X-100 for containing 0.2%)
Born of the same parents are dispelled, and dilution rear plate is counted;
6th, HP0623 is counted to the SEZ inhibiting rates for adhering to Hep-2 cells by equation below:
Inhibiting rate=[1- (bacterial population of the cell of the bacterial population of the cell of HP0623 processing/BSA processing)] × 100%.
Experimental result:RHP0623 can suppress adhesions of the SEZ to Hep-2 cells, as shown in Figure 10, compared to control group,
Inhibiting rate is 14.9%.
From above-described embodiment as can be seen that Malian drainage protective antigens HP0623 of the present invention preparation
Method, including target gene clone, digestion enzyme company, induced expression, protein purification.HP0623 albumen is recombinated through protein immunization imprinting
Analysis, shows that it has good immune response originality.In mice serum after recombinant protein is immune antibody titer apparently higher than
In negative control group mouse, and the Antibody types of immune mouse generation, IgG1 titres are higher than IgG2a.Mouse is immunized in rHP0623
Stronger Vaccine effectiveness can be provided for mouse afterwards, anti-rHP0623 mouse two, which exempt from serum, obvious passive protection to mouse
Power, anti-rHP0623 antibody can be with the sterilizing ability of induced high levels.Sez_0623 genes are in the Mice Body that SEZ infects
Transcriptional level is higher than the transcriptional level of in vitro culture, and Flow cytometry result shows, HP0623 is located at SEZ surfaces,
RHP0623 can suppress adhesions of the SEZ to Hep-2 cells, and inhibiting rate is 14.9%.
Embodiment described above only expresses the several embodiments of the present invention, and it describes more specific and detailed, but simultaneously
Therefore the limitation of the scope of the claims of the present invention can not be interpreted as.For the person of ordinary skill of the art, this is not being departed from
On the premise of inventive concept, some denaturation and improvement can also be made, these belong to protection scope of the present invention.Therefore, originally
The protection domain of patent of invention should be determined by the appended claims.
SEQUENCE LISTING
<110>Hubei University
<120>A kind of Malian drainage protective antigens HP0623 and preparation method thereof
<130> 2017.5
<160> 8
<170> PatentIn version 3.3
<210> 1
<211> 753
<212> DNA
<213>Malian drainage
<400> 1
gcttgcctgc tagtgctaac aacctttatt tatcagtgct gttcagttac tgctgagcag 60
tattctgata ctgaggctga ggtgctgcag attaacgagg agaaaagcca gatcatggaa 120
agtcaagagg tgcttgaagg cctcatcacg tcgtctgatc agctaaagaa gaaagcttta 180
aagcctaaag aggcagctac caacaagagc aagcaagagg cttcgacagt ttatttagct 240
gaggacgatc ctgtaaccat tgatagctct gacgaggaaa gcaatcgaga tattatagcg 300
gattctgttc ctgatttggt tattaaaggt gatcaggtgg atgtatctga ggttatggtc 360
tctgtaaagg aggatccatc gaaagttgct aagcaaagaa caaacgcagc gcagcggtat 420
agtatagcca agcatcaatt gacccaaaag cttgaggcct ttaatgcggc aacggaccaa 480
ttgctgacca tgattgctaa aaaatctgat ttgactggtc agtattatgt ggttgggcat 540
tcgttgggag aaatgctggc tgctcaaaat gagaaaaagc ttgctgagca attagtcatg 600
caacaaaagc acaaaaaagg cttagactca tcagccacta ttttagacga attaggacgt 660
gtgatttctg acattagtgg tcataaaggt atgcttcctt ttaatcgtaa gatcagcttt 720
aaagcacatc aggtcagata cgatcttccc ctc 753
<210> 2
<211> 429
<212> PRT
<213>Malian drainage
<400> 2
Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp
1 5 10 15
Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp
20 25 30
Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp
35 40 45
Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn
50 55 60
Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu
65 70 75 80
Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser
85 90 95
Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly
100 105 110
Ser Gly His Met His His His His His His Ser Ser Gly Leu Val Pro
115 120 125
Arg Gly Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln
130 135 140
His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Ala Met
145 150 155 160
Ala Asp Ile Gly Ser Ala Cys Leu Leu Val Leu Thr Thr Phe Ile Tyr
165 170 175
Gln Cys Cys Ser Val Thr Ala Glu Gln Tyr Ser Asp Thr Glu Ala Glu
180 185 190
Val Leu Gln Ile Asn Glu Glu Lys Ser Gln Ile Met Glu Ser Gln Glu
195 200 205
Val Leu Glu Gly Leu Ile Thr Ser Ser Asp Gln Leu Lys Lys Lys Ala
210 215 220
Leu Lys Pro Lys Glu Ala Ala Thr Asn Lys Ser Lys Gln Glu Ala Ser
225 230 235 240
Thr Val Tyr Leu Ala Glu Asp Asp Pro Val Thr Ile Asp Ser Ser Asp
245 250 255
Glu Glu Ser Asn Arg Asp Ile Ile Ala Asp Ser Val Pro Asp Leu Val
260 265 270
Ile Lys Gly Asp Gln Val Asp Val Ser Glu Val Met Val Ser Val Lys
275 280 285
Glu Asp Pro Ser Lys Val Ala Lys Gln Arg Thr Asn Ala Ala Gln Arg
290 295 300
Tyr Ser Ile Ala Lys His Gln Leu Thr Gln Lys Leu Glu Ala Phe Asn
305 310 315 320
Ala Ala Thr Asp Gln Leu Leu Thr Met Ile Ala Lys Lys Ser Asp Leu
325 330 335
Thr Gly Gln Tyr Tyr Val Val Gly His Ser Leu Gly Glu Met Leu Ala
340 345 350
Ala Gln Asn Glu Lys Lys Leu Ala Glu Gln Leu Val Met Gln Gln Lys
355 360 365
His Lys Lys Gly Leu Asp Ser Ser Ala Thr Ile Leu Asp Glu Leu Gly
370 375 380
Arg Val Ile Ser Asp Ile Ser Gly His Lys Gly Met Leu Pro Phe Asn
385 390 395 400
Arg Lys Ile Ser Phe Lys Ala His Gln Val Arg Tyr Asp Leu Pro Leu
405 410 415
Lys Leu Ala Ala Ala Leu Glu His His His His His His
420 425
<210> 3
<211> 24
<212> DNA
<213>Artificial sequence primer11
<400> 3
cccggatccgcttgcctgctagtg 24
<210> 4
<211> 26
<212> DNA
<213>Artificial sequence primer12
<400> 4
ctcaagcttgaggggaagatcgtatc 26
<210> 5
<211> 19
<212> DNA
<213>Artificial sequence primer21
<400> 5
cggtatagtatagccaagc 19
<210> 6
<211> 16
<212> DNA
<213>Artificial sequence primer22
<400> 6
gcatttctcccaacga 16
<210> 7
<211> 18
<212> DNA
<213>Artificial sequence primer31
<400> 7
atccgaactgagattggc 18
<210> 8
<211> 18
<212> DNA
<213>Artificial sequence primer32
<400> 8
cccttatgacctgggcta 18
Claims (7)
1. a kind of Malian drainage protective antigens HP0623, it is characterised in that:For SEZ HP0623 recombinant proteins, by
Sez_0623 gene codes, are made up of 429 amino acid residues, and molecular weight is 47.04kDa, amino acid sequence such as SEQ ID
Shown in NO.2.
2. a kind of Malian drainage protective antigens HP0623 preparation method, is divided into following steps:
1) PCR is expanded:The use of Malian drainage SEZ C55138 genomes is template, entering performing PCR with primer expands;
2) connection of carrier:PCR primer is connected after digestion with restriction enzyme with PET-32a carriers;
3) convert and induce:By step 2) carrier that connects converts to Escherichia coli, cultivates to OD values to 0.6~1.0, plus
Enter IPTG Fiber differentiations 3-5h;
4) purify:Step 3 is collected by centrifugation) in cultured thalline, with sterile PBS be resuspended after after crushing, albumen is collected by centrifugation
Supernatant, takes supernatant through Ni-NTA column chromatographies, obtains the recombinant protein of purifying, as Malian drainage protectiveness
Antigen HP0623.
3. Malian drainage protective antigens HP0623 according to claim 2 preparation method, its feature exists
In:The primer is:
Forward primer:5’-CCCGGATCCGCTTGCCTGCTAGTG-3’;
Reverse primer:5’-CTCAAGCTTGAGGGGAAGATCGTATC-3’。
4. Malian drainage protective antigens HP0623 according to claim 3 preparation method, its feature exists
In:The forward primer and reverse primer have 1 restriction enzyme site respectively.
5. Malian drainage protective antigens HP0623 according to claim 4 preparation method, its feature exists
In:The restriction enzyme site of the forward primer is BamH I restriction enzyme sites;Reverse primer restriction enzyme site is Hind III digestions site.
6. Malian drainage protective antigens HP0623 is preparing Malian drainage according to claim 1
Application in vaccine.
7. a kind of method that Malian drainage protective antigens HP0623 prepares Malian drainage vaccine, it is special
Levy and be:By step 4 described in any claim in claim 2-5) purification process obtained recombinant protein and Montanide
It is Malian drainage vaccine after the PR adjuvant emulsions of Gel 01, the concentration of the recombinant protein is 100 μ g/mL.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710395446.2A CN107129527B (en) | 2017-05-26 | 2017-05-26 | Streptococcus equi subsp zooepidemicus protective antigen HP0623 and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710395446.2A CN107129527B (en) | 2017-05-26 | 2017-05-26 | Streptococcus equi subsp zooepidemicus protective antigen HP0623 and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107129527A true CN107129527A (en) | 2017-09-05 |
CN107129527B CN107129527B (en) | 2020-05-22 |
Family
ID=59734109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710395446.2A Expired - Fee Related CN107129527B (en) | 2017-05-26 | 2017-05-26 | Streptococcus equi subsp zooepidemicus protective antigen HP0623 and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107129527B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111499702A (en) * | 2020-05-07 | 2020-08-07 | 山东畜牧兽医职业学院 | Detection kit and detection method for streptococcus equi subsp zooepidemicus |
CN113999305A (en) * | 2021-11-03 | 2022-02-01 | 南京农业大学 | Preparation and application of monoclonal antibody of streptococcus equi zooepidemicus SzM protein |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102746388A (en) * | 2012-07-02 | 2012-10-24 | 中山大学 | Streptococcus protective antigen C5a and preparation method thereof |
CN102746389A (en) * | 2012-07-02 | 2012-10-24 | 中山大学 | Streptococcus adhesion antigen GAPDH and preparation method thereof |
CN106008680A (en) * | 2016-05-27 | 2016-10-12 | 佛山科学技术学院 | Streptococcus protective antigen SAP and preparation method thereof |
-
2017
- 2017-05-26 CN CN201710395446.2A patent/CN107129527B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102746388A (en) * | 2012-07-02 | 2012-10-24 | 中山大学 | Streptococcus protective antigen C5a and preparation method thereof |
CN102746389A (en) * | 2012-07-02 | 2012-10-24 | 中山大学 | Streptococcus adhesion antigen GAPDH and preparation method thereof |
CN106008680A (en) * | 2016-05-27 | 2016-10-12 | 佛山科学技术学院 | Streptococcus protective antigen SAP and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
佚名: "" KIS13840.1"", 《GENBANK》 * |
佚名: ""WP_012515266.1"", 《GENBANK》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111499702A (en) * | 2020-05-07 | 2020-08-07 | 山东畜牧兽医职业学院 | Detection kit and detection method for streptococcus equi subsp zooepidemicus |
CN111499702B (en) * | 2020-05-07 | 2021-04-06 | 山东畜牧兽医职业学院 | Detection kit and detection method for streptococcus equi subsp zooepidemicus |
CN113999305A (en) * | 2021-11-03 | 2022-02-01 | 南京农业大学 | Preparation and application of monoclonal antibody of streptococcus equi zooepidemicus SzM protein |
Also Published As
Publication number | Publication date |
---|---|
CN107129527B (en) | 2020-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110093324B (en) | Attenuated African swine fever virus with gene deletion and application thereof as vaccine | |
CN103172749B (en) | Preparation of African swine fever protein engineering vaccine | |
Ikegami et al. | Rift valley fever vaccines | |
CN113186173B (en) | Novel coronavirus pneumonia vaccine based on attenuated influenza virus vector | |
Gong et al. | Immune efficacy of DNA vaccines based on oprL and oprF genes of Pseudomonas aeruginosa in chickens | |
CN113943714B (en) | Callicarpa virus strain and application thereof | |
CN110872578B (en) | Variant infectious bursal disease virus, subunit vaccine, preparation method and application thereof | |
CN104628871B (en) | A kind of preparation for recombinating bursal disease protein engineering vaccine | |
CN104628865B (en) | A kind of pseudo- mad dog epitope polypeptide recombinant vaccine | |
CN102816246B (en) | Human cytomegalo virus immunogen fusion protein as well as preparation method and usage thereof | |
Zheng et al. | A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice | |
CN106928373A (en) | A kind of porcine mycoplasmal pneumonia multi-epitope mucosal vaccine | |
Zhao et al. | Assessments of different inactivating reagents in formulating transmissible gastroenteritis virus vaccine | |
CN107129527A (en) | A kind of Malian drainage protective antigens HP0623 and preparation method thereof | |
CN1909925B (en) | Immunologic adjuvant | |
CN116813718B (en) | Recombinant porcine circovirus 2 type Cap protein trimer, expression system and application thereof | |
CN103561763A (en) | Immunogenic bordetella bronchiseptica compositions | |
CN102010876A (en) | Recombinant bacillus subtilis EV71-VP1 expression vector and preparation method and application thereof | |
CN106031793B (en) | Live vaccine and preparation method and application thereof | |
CN109021115A (en) | A kind of pig circular ring virus trivalent subunit vaccine | |
CN117431200A (en) | Recombinant bacillus subtilis for displaying Newcastle disease virus HN protein on spore surface, construction method and application | |
CN105797152A (en) | Vaccine composition and its preparation method and use | |
CN104804099B (en) | A kind of reinforced polyepitope vaccines of recombination H9N2 subtype avian influenza | |
CN102847168B (en) | The design of a kind of nucleic acid vaccine PV-Fn preventing bovine mastitis and structure thereof | |
CN107353329A (en) | A kind of Malian drainage protective antigens Sec_205 and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200522 Termination date: 20210526 |